Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 5 art units • 10 examiners • 0 of 12 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Ipsen Biopharm Limited operates a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. There are 11 pending office actions currently active. These actions are distributed across 9 distinct examiners and 5 distinct art units. SWIFT, CANDICE LEE is the busiest examiner with 2 pending actions. The presence of 11 pending office actions suggests a steady volume of ongoing prosecution within the biotechnology sector.
The ratio of 11 pending office actions to 9 distinct examiners suggests that most examiners are handling a single matter. With 5 distinct art units involved, the company's pharmaceutical prosecution is moderately diversified across different technical specialties. Practitioners should note the involvement of 9 distinct examiners when managing these actions. The concentration of 2 pending actions with a single examiner represents the highest point of individual examiner engagement. This structure requires a strategy that accounts for varied examiner styles across the 5 distinct art units while monitoring the specific progress of the busiest examiner.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 6 (50%) |
| Multi-statute (no §101) | 6 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SWIFT, CANDICE LEE | 2 | 57.5% | +36.0% |
| DAVIS, RUTH A | 2 | 60.8% | +31.1% |
| DUFFY, PATRICIA ANN | 1 | 52.9% | +33.9% |
| GANGLE, BRIAN J | 1 | 76.7% | +14.7% |
| JACKSON-TONGUE, LAKIA J | 1 | 69.0% | +20.8% |
| GRASER, JENNIFER E | 1 | 76.7% | +23.4% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.7% | +41.4% |
| PAGUIO FRISING, MICHELLE F | 1 | 71.1% | +39.3% |
| CLARKE, TRENT R | 1 | 42.0% | +24.0% |
| RAGHU, GANAPATHIRAM | 1 | 73.6% | +26.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17759674 | TREATMENT OF SKIN CONDITIONS | DAVIS, RUTH A | 40d |
| 19309183 | CHIMERIC NEUROTOXINS | DUFFY, PATRICIA ANN | — |
| 18914188 | TREATMENT OF AUTONOMIC DISORDERS WITH BOTULINUM TOXIN | JACKSON-TONGUE, LAKIA J | — |
| 18711047 | TREATMENT OF VISCERAL PAIN | GRASER, JENNIFER E | — |
| 18003570 | CONTROLLING OPERATION OF A BIOREACTOR VESSEL | CLARKE, TRENT R | — |
| 18003489 | TREATMENT OF POST-OPERATIVE SURGICAL PAIN | RAGHU, GANAPATHIRAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18096899 | TREATMENT OF MODERATE TO VERY SEVERE GLABELLAR LINES AND LATERAL CANTHAL LINES | DAVIS, RUTH A | 34d |
| 17759674 | TREATMENT OF SKIN CONDITIONS | DAVIS, RUTH A | 40d |
| 19309183 | CHIMERIC NEUROTOXINS | DUFFY, PATRICIA ANN | — |
| 19189864 | LIQUID NEUROTOXIN FORMULATION STABILIZED WITH TRYPTOPHAN OR TYROSINE | GANGLE, BRIAN J | — |
| 18914188 | TREATMENT OF AUTONOMIC DISORDERS WITH BOTULINUM TOXIN | JACKSON-TONGUE, LAKIA J | — |
| 18711047 | TREATMENT OF VISCERAL PAIN | GRASER, JENNIFER E | — |
| 18711074 | TREATMENT OF PAIN | OGUNBIYI, OLUWATOSIN A | — |
| 18690479 | Modified Bont/A for Use in the Treatment of a Disorder Affecting an Eyelid Muscle of a Subject | SWIFT, CANDICE LEE | — |
| Art Unit | Apps |
|---|---|
| 1645 | 3 |
| 1657 | 2 |
| 1651 | 2 |
| 1699 | 2 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19309183 | CHIMERIC NEUROTOXINS | DUFFY, PATRICIA ANN | 1645 | §102§103Other | Non-Final OA | — | Pending | Aug 25, 2025 |
| 19189864 | LIQUID NEUROTOXIN FORMULATION STABILIZED WITH TRYPTOPHAN OR TYROSINE | GANGLE, BRIAN J | — | §112DP | Non-Final OA | — | Pending | Apr 25, 2025 |
| 18914188 | TREATMENT OF AUTONOMIC DISORDERS WITH BOTULINUM TOXIN | JACKSON-TONGUE, LAKIA J | — | §102§103§112 | Non-Final OA | — | Pending | Oct 13, 2024 |
| 18711047 | TREATMENT OF VISCERAL PAIN | GRASER, JENNIFER E | 1645 | §103§112 | Non-Final OA | — | Pending | May 16, 2024 |
| 18711074 | TREATMENT OF PAIN | OGUNBIYI, OLUWATOSIN A | 1645 | §102§103DP | Non-Final OA | — | Pending | May 16, 2024 |
| 18690479 | Modified Bont/A for Use in the Treatment of a Disorder Affecting an Eyelid Muscle of a Subject | SWIFT, CANDICE LEE | 1657 | §103§112DP | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18690378 | Modified Bont/A for Use in the Treatment of Cervical Dystonia | SWIFT, CANDICE LEE | 1657 | §103§112DP | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18552457 | CATALYTICALLY INACTIVE CLOSTRIDIAL NEUROTOXINS FOR THE TREATMENT OF PAIN & INFLAMMATORY DISORDERS | PAGUIO FRISING, MICHELLE F | 1651 | §102§103DP | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18096899 | TREATMENT OF MODERATE TO VERY SEVERE GLABELLAR LINES AND LATERAL CANTHAL LINES | DAVIS, RUTH A | 1699 | §112DPOther | Final Rejection | 34d | Pending | Jan 13, 2023 |
| 18003570 | CONTROLLING OPERATION OF A BIOREACTOR VESSEL | CLARKE, TRENT R | 1651 | §102§103§112 | Non-Final OA | — | Pending | Dec 28, 2022 |
| 18003489 | TREATMENT OF POST-OPERATIVE SURGICAL PAIN | RAGHU, GANAPATHIRAM | 1652 | §102§103§112 | Final Rejection | — | Pending | Dec 27, 2022 |
| 17759674 | TREATMENT OF SKIN CONDITIONS | DAVIS, RUTH A | 1699 | §102§103§112Other | Non-Final OA | 40d | Pending | Jul 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial